The present invention discloses novel method for synthesizing vegan cholesterol and vitamin D3 from inexpensive crude phytosterol.

Provided herein is a compound of Formula (1-I): or a pharmaceutically acceptable salt thereof, wherein R.sup.2a, R.sup.2b, R.sup.3, R.sup.4a, R.sup.4b, R.sup.5, R.sup.6a, R.sup.6b, R.sup.11a, R.sup.11b, R.sup.16a, R.sup.16b, R.sup.19, R.sup.18, X, q, r, s, t, u, and n are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (1-I) and methods of using the compounds, e.g, in the treatment of CNS-related disorders.

##STR00001##

The present disclosure is concerned with taccalonolide analogs and conjugated taccalonolide analogs useful as cellular probes and in the treatment of, for example, hyperproliferative disorders such as cardiovascular diseases and cancer. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Steroid derivative regulators, a method for preparing the same, and uses thereof are described. Specifically, a compound as shown in formula (I), a preparation method therefor, a pharmaceutical composition containing the compound, and uses thereof as a regulator of GABA .sub.A receptor for treating depression, convulsion, Parkinson's disease, and nervous system diseases are described, wherein the substituents of the formula (I) are as defined in the description. ##STR00001##

The present invention relates to the unexpected discovery of novel monomer compounds capable of crosslinking interpenetrating polymer networks (IPNs). In certain embodiments, the monomer compounds of the invention each comprise at least one methacrylate functionality capable of forming polymeric bonds with other methacrylate and vinyl functionalities, and at least one epoxide functionality capable of forming polymeric bonds with epoxide functionalities, amine functionalities, and/or reactive oxygen species.

This invention provides novel compounds comprising the following anti-inflammatory pharmacore: ##STR00001##
wherein X, R.sub.1 and R.sub.2 are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds, methods and intermediates useful for making the compounds, and methods of using the compounds and compositions.

A novel glycyrrhetinic acid derivative. The glycyrrhetinic acid derivative is represented by the following general formula. ##STR00001##

Amphiphilic compounds with tetradecahydrophenanthrene skeleton and their enantiomers, exhibiting neuroprotective effects, their use in methods of treatment of neuropsychiatric disorders associated with an imbalance in glutamatergic neurotransmitter system, such as ischemic damage of CNS, neurodegenerative changes and disorders of CNS, affective disorders, depression, post-traumatic stress disorder and diseases related to stress, anxiety, schizophrenia and psychotic disorders, pain, addiction, multiple sclerosis, epilepsy, glioma, and a pharmaceutical composition containing compound.

A new process for enriching triterpene esters comprising: providing a mixture comprising a non-distilled vegetable oil and/or a non-distilled vegetable fat, further comprising triterpene esters, performing a mild transesterification with a lower alcohol, removing lower alcohol esters by deodorization, physical refining, evaporation or distillation, and recovering the remaining fraction rich in triterpene esters. Triterpene esters enriched with the method as well as uses of the same are also provided. One advantage is that it is a more economically viable way of achieving higher concentration of triterpene esters. There is both the chance to fully keep the natural distribution of triterpene esters but in the other end also to replace the natural level of cinnamic and acetic acids-triterpene esters with a high level of long fatty acid triterpene-esters.

A method for preparing oryzanol from oryzanol-containing soapstock as a raw material includes the following steps: 1) alkali-alcohol thermal dissolution; 2) heat-preserved fine filtration; 3) heat-preserved ultrafiltration membrane separation; 4) heat-preserved decolorization; 5) acid neutralization and filtration; 6) washing; and 7) drying. The temperatures of the step 1) to the step 4) are controlled at 50-60° C. The method has a heat preservation operation at 50-60° C., membrane separation, decolorization and washing, to finally prepare a white powdered product. The purity of product oryzanol is greater than 98% and the yield is greater than 73%. The method does not use toxic or combustible or explosive organic solvents such as methanol, ether, hexane and solvent oil, so that the product use safety is improved; the production process is simple, has low requirements on production equipment, is easy to operate and realize, and is low in production cost and suitable for industrial production.